Hetero

As per the US health regulator's latest Enforcement Report, the US-based arm of Sun Pharmaceutical Industries is recalling a generic drug indicated to raise blood pressure in adult patients with acute hypotension.

COVID-19 continues to surge in India but Paxlovid is only a minor player

Apart from reducing hospitalisation for the most vulnerable group and its efficacy against Omicron variants, Paxlovid has also shown to decrease the chances of long COVID-19.

Hetero to invest Rs 1,000 crore in AP over two years to expand pharma business

Speaking at Global Investors Summit 2023 here, he said post-Covid pandemic, more countries are looking at India as a partner of choice in pharmaceutical sector, and Andhra Pradesh is ideally placed to take advantage because of a well-established ecosystem.

All you need to know about Paxlovid, the most promising COVID-19 drug

US-based Pfizer has signed a licensing agreement for Paxlovid with 30 drugmakers globally, including 19 Indian companies. Hetero and Zenara have said they received regulatory approvals for their versions of Paxlovid

Nirmacom - Hetero's COVID-19 generic for Paxlovid gets key WHO support

A press release from the drug maker said it is the first prequalification for a generic version of Pfizer's COVID-19 oral anti-viral drug 'Paxlovid,' which the WHO called, the best therapeutic choice for high-risk patients to date.

Hetero acquires Johnson & Johnson's manufacturing plant in Telangana

According to sources, the company has acquired the plant for Rs 130 crore.

Big Story | Cipla, Hetero get regulator nod for Remdesivir: What this means for COVID-19 patients

Remdesivir has emerged as one of the most promising drug candidates in the treatment of COVID-19

Hetero launches generic breast cancer treatment drug in India

The tablets, under the brand name 'Hertab', have been launched in the strength of 250 mg, the company said.

Sub-license for Hepatitis C drug beneficial for patients: Cipla

Jaideep Gogtay, Clinical Head at Cipla pointed out that in India the cost of treatment of Hepatitis C ranges between Rs 75,000 to Rs 1.5 lakh per patient, depending on the type of virus and the intensity.

Cipla likely to acquire Hetero Drugs' US business: Sources

Homegrown drug major Cipla is in advance stage talks to acquire Hetero Drugs' US business, which is run under the Camber Pharmaceuticals brand.

See Rs 400cr increase in top line over next few yrs: Hetero

The company has 20 facilities across the globe with portfolio of more than 200 products in 138 countries.